subscribeSubscribe
Subcutaneous Trastuzumab Proves Safe and Tolerable in HER2+ MBC

Subcutaneous Trastuzumab Proves Safe and Tolerable in HER2+ MBC
ONCLIVE
28 Aug 2023
Share Share
Keytruda combination hits primary endpoint in a rare form of gastric cancer

Keytruda combination hits primary endpoint in a rare form of gastric cancer
Tyler Patchen YAHOO FINANCE
17 Jun 2023
Share Share
Long-term Ph3 Results Show Similar Efficacy, Cardiac Safety of SB3 vs Herceptin

Long-term Ph3 Results Show Similar Efficacy, Cardiac Safety of SB3 vs Herceptin
CENTERFORBIOSIMILARS
06 May 2023
Share Share
‘EMA’s refusal to authorize Herceptin biosimilar unfair’

‘EMA’s refusal to authorize Herceptin biosimilar unfair’
KOREABIOMED
23 May 2022
Share Share
Result of Phase 3 Study for Prestige’s HD201 Published in JAMA Oncology

Result of Phase 3 Study for Prestige’s HD201 Published in JAMA Oncology
BUSINESSWIRE
11 Mar 2022
Share Share
BMS` Opdivo hits more approvable goal in early NSCLC

BMS` Opdivo hits more approvable goal in early NSCLC
Aakash Babu SEEKINGALPHA
09 Nov 2021
Share Share
Seagen undaunted by AstraZeneca-Daiichi`s Enhertu

Seagen undaunted by AstraZeneca-Daiichi`s Enhertu
K. Dunleavy FIERCEPHARMA
30 Oct 2021
Share Share
GSK`s Shingrix rebound has yet to materialize, analysts say

GSK`s Shingrix rebound has yet to materialize, analysts say
Kevin Dunleavy FIERCEPHARMA
16 Sep 2021
Share Share
ESMO: Zymeworks lays down marker in fight to unseat Herceptin

ESMO: Zymeworks lays down marker in fight to unseat Herceptin
N. P. Taylor FIERCEBIOTECH
16 Sep 2021
Share Share
MacroGenics wins breast cancer nod with Herceptin-topping data

MacroGenics wins breast cancer nod with Herceptin-topping data
Angus Liu FIERCE PHARMA
18 Dec 2020
Share Share